SEC Charges Zymergen Inc. With Misleading IPO Investors About Company’s Market Potential and Sales Prospects
Zymergen Inc. agreed to pay a $30 million civil penalty to settle SEC charges for misleading IPO investors about the market potential and revenue prospects of its Hyaline product.
Zymergen Inc. settled SEC charges for violating antifraud provisions by misrepresenting the market opportunity and customer pipeline for its Hyaline product. The company used flawed assumptions to claim a $1 billion market potential and provided revenue forecasts that far exceeded internal estimates. To resolve the matter, Zymergen agreed to a $30 million civil penalty and a cease-and-desist order, subject to bankruptcy court approval.
The SEC announced settled charges against Emeryville-based biotechnology company Zymergen Inc. for misleading investors during its April 2021 IPO. The company raised approximately $530 million through the offering but later filed for bankruptcy in 2023. According to the SEC, Zymergen falsely claimed a $1 billion market opportunity for its Hyaline product based on unreasonable assumptions and unsupported premium pricing. Additionally, the company provided misleading revenue forecasts to analysts and misrepresented its customer pipeline while omitting significant technical and commercial issues. To resolve these antifraud violations, Zymergen agreed to a $30 million civil penalty and a cease-and-desist order. This settlement remains subject to approval by the bankruptcy court and was reached without the company admitting or denying the findings.
Exhibits & Attached Documents (1)
Extracted insights
- $1.00B $1 billion ≥$1B
- $530.00M $530 million $100M–$1B
- $30.00M $30 million $10M–$100M
- person monique c. winkler
- agency Securities and Exchange Commission
- company zymergen inc.
- Securities and Exchange Commission announced settled charges Zymergen Inc.
- Zymergen raised approximately $530 million through its IPO in April 2021
- Zymergen filed for bankruptcy 2023
- Zymergen agreed to pay $30 million civil penalty
- Zymergen claimed $1 billion electronics display market opportunity for Hyaline
- Zymergen provided misleading revenue forecasts to research analysts
- Zymergen misled investors during its first public earnings call
- Monique C. Winkler said Zymergen failed to satisfy this obligation
- Zymergen violated certain antifraud provisions of the federal securities laws
- Zymergen agreed to cease-and-desist order
The Securities and Exchange Commission today announced settled charges against Zymergen Inc., an Emeryville, California-based biotechnology company, for misleading IPO investors about its overall market potential, revenue prospects, and customer pipeline for its only commercially available product, an electronics film named Hyaline. Zymergen raised approximately $530 million through its IPO in April 2021 and filed for bankruptcy in 2023. Zymergen agreed to pay a $30 million civil penalty to resolve the SEC’s charges. According to the SEC’s order, Zymergen claimed that it had a $1 billion electronics display market opportunity for Hyaline, but the estimate was based on flawed and unreasonable assumptions that included product markets that were poor fits for Hyaline’s technical characteristics and unsupported premium pricing. The SEC’s order also finds that Zymergen provided misleading revenue forecasts to research analysts that far exceeded internal estimates. Additionally, the order finds that Zymergen misled investors during its first public earnings call by misrepresenting the status of Hyaline’s customer pipeline while omitting significant technical and commercial problems facing the product. “Pre-revenue and early-stage companies that seek to tap the capital markets must do so with reasonable estimates of their market potential,” said Monique C. Winkler, Director of the SEC’s San Francisco Regional Office. “Today’s order finds that Zymergen failed to satisfy this obligation when it misled investors with what amounted to unsupported hype.” The SEC’s order finds that Zymergen violated certain antifraud provisions of the federal securities laws. Without admitting or denying the SEC’s findings, and subject to bankruptcy court approval, Zymergen agreed to a cease-and-desist order and to pay the civil penalty referenced above. The SEC’s investigation was conducted by Anthony Moreno and Eli Greenstein of the San Francisco Regional Office, with assistance from David Baddley and Brent Smyth, and was supervised by Rahul Kolhatkar, Alistaire Bambach, and Jason H. Lee.
The Securities and Exchange Commission today announced settled charges against Zymergen Inc., an Emeryville, California-based biotechnology company, for misleading IPO investors about its overall market potential, revenue prospects, and customer pipeline for its only commercially available product, an electronics film named Hyaline. Zymergen raised approximately $530 million through its IPO in April 2021 and filed for bankruptcy in 2023. Zymergen agreed to pay a $30 million civil penalty to resolve the SEC’s charges. According to the SEC’s order, Zymergen claimed that it had a $1 billion electronics display market opportunity for Hyaline, but the estimate was based on flawed and unreasonable assumptions that included product markets that were poor fits for Hyaline’s technical characteristics and unsupported premium pricing. The SEC’s order also finds that Zymergen provided misleading revenue forecasts to research analysts that far exceeded internal estimates. Additionally, the order finds that Zymergen misled investors during its first public earnings call by misrepresenting the status of Hyaline’s customer pipeline while omitting significant technical and commercial problems facing the product. “Pre-revenue and early-stage companies that seek to tap the capital markets must do so with reasonable estimates of their market potential,” said Monique C. Winkler, Director of the SEC’s San Francisco Regional Office. “Today’s order finds that Zymergen failed to satisfy this obligation when it misled investors with what amounted to unsupported hype.” The SEC’s order finds that Zymergen violated certain antifraud provisions of the federal securities laws. Without admitting or denying the SEC’s findings, and subject to bankruptcy court approval, Zymergen agreed to a cease-and-desist order and to pay the civil penalty referenced above. The SEC’s investigation was conducted by Anthony Moreno and Eli Greenstein of the San Francisco Regional Office, with assistance from David Baddley and Brent Smyth, and was supervised by Rahul Kolhatkar, Alistaire Bambach, and Jason H. Lee.